Q: https://www.google.ca/amp/s/finance.yahoo.com/amphtml/news/biohaven-bhvn-q2-nurtec-preliminary-152303082.html
Could you please comment on the recent results and based on these updated results have your previous concerns that you’ve mentioned in past comments changed for the better…would Biohaven be a take out candidate and with all the higher price targets, the insider buying by the CEO, what a your future thoughts on the company and their balance sheet if they keep this up. Would you buy, sell or hold here? and how would they be able to compete with other big pharma companies in the migraine space going forward?
Could you please comment on the recent results and based on these updated results have your previous concerns that you’ve mentioned in past comments changed for the better…would Biohaven be a take out candidate and with all the higher price targets, the insider buying by the CEO, what a your future thoughts on the company and their balance sheet if they keep this up. Would you buy, sell or hold here? and how would they be able to compete with other big pharma companies in the migraine space going forward?